Clinical and humanistic outcomes of pharmaceutical care interventions in diabetes mellitus: a systematic review and meta-analysis
Main Article Content
Abstract
Background: Diabetes mellitus is a chronic disease for which life-long medications and care are needed. Effectiveness of care is related to good glycemic control, which is desired to forestall complications.
Objective: This study evaluated the effectiveness of pharmaceutical care (PC) services provided by pharmacists in improving clinical and humanistic outcomes in diabetes mellitus patients.
Method: Five databases (PubMed/Medline, Embase, Scopus, Cochrane Central Register of Control Trials and Google Scholar) were systematically searched for randomized controlled trials (RCTs) reported in English using free text and medical subject headings keywords. Studies which had PC intervention arm, a control group, type1 and type 2 diabetes mellitus patients; clinical and/or humanistic outcomes were included. For metaanalysis, standard mean difference evaluated with random effect model at P<0.05 was reported. Significant heterogeneity was further evaluated with sensitivity and subgroup analyses.
Results: A total of 41 RCTs with 7,448 patients were eligible out of 1222 citations. PC intervention significantly lowered glycosylated hemoglobin, fasting blood glucose, systolic blood pressure, diastolic blood pressure, total cholesterol, and low density lipoprotein cholesterol (P < 0.05), with significant heterogeneity. PC intervention also improved self-care but medication adherence, disease knowledge and quality of life were not improved. PC services offered (patient education, identification and resolution of drug therapy problems, and pharmacotherapy evaluation) were not uniform across the studies.
Conclusion: The review and meta-analysis showed that PC intervention is of great benefit to improve most clinical outcomes which may result in better disease management. A call is however made for standardized pharmaceutical care intervention.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
World Health Organization (2016). Global report on diabetes (World Health Organization).
Oparah AC, Famakinde AJ, and OJA. (2009). Outcomes of pharmacists' interventions in the collaborative care of patients with diabetes.
Pharmacy Education 9:18-22.
Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, and McElnay JC. (2009). Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. British Journal of Clinical Pharmacology 67: 547-557.
Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, and Holman RR. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321: 405-412.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, and Matthews DR. (2012).
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association
(ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, Tan E, Chan SC, Chia A, Sinaram SS, et al. (2017). Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. Journal of Clinical Pharmacy Therapeutics 42: 475-482.
Phumipamorn S, Pongwecharak J, Soorapan S, and Pattharachayakul S. (2008). Effects of the pharmacist's input on glycaemic control and
cardiovascular risks in Muslim diabetes. Primary Care Diabetes 2: 31-37.
Sakthong P, and Sangthonganotai T. (2018). A randomized controlled trial of the impact of pharmacist-led patient-centered pharmaceutical care on patients' medicine therapy-related quality of life. Research in Social and Administrative Pharmacy 14: 332-339.
Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, and Khan TM. (2016). Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pakistan Journal of Pharmaceutical Sciences 29: 595-601.
Nathan DM, and Group DR. (2014). The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care 37: 9-16.
Aguiar PM, Brito G de C, Lima T de M, Santos APAL., Lyra DP, and Storpirtis S. (2016). Investigating Sources of Heterogeneity in
Randomized Controlled Trials of the Effects of Pharmacist Interventions on Glycemic Control in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis. PLoS ONE 11: e0150999.
Collins C, Limone BL, Scholle JM, and Coleman CI. (2011). Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Research and Clinical Practice 92: 145-152.
Honkasalo MT, Linna M, Sane T, Honkasalo A, and Elonheimo O. (2014). A comparative study of two various models of organising diabetes follow-up in public primary health care-the model influences the use of services, their quality and costs. BMC Health Services Research 14: 26.
Leach MJ, Segal L, Esterman A, Armour C, McDermott R, and Fountaine T. (2013). The Diabetes Care Project: an Australian multicentre,
cluster randomised controlled trial [study protocol]. BMC Public Health 13: 1212.
Clifford RM, Batty KT, Davis TM, Davis W, Stein G, Stewart G, and Plumridge RJ. (2002). A randomised controlled trial of a pharmaceutical
care programme in high-risk diabetic patients in an outpatient clinic. International Journal of Pharmacy Practice 10: 85-89.
Wishah RA, Al-Khawaldeh OA, and Albsoul AM. (2015). Impact of pharmaceutical care interventions on glycemic control and other
health-related clinical outcomes in patients with type 2 diabetes: Randomized controlled trial. Diabetes & Metabolic Syndrome: Clinical
Research & Reviews 9: 271-276.
Shao H, Chen G, Zhu C, Chen Y, Liu Y, He Y, and Jin H. (2017). Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus. Patient Preference and Adherence 11: 897-903.
Adibe MO, Udeogaranya PO, Igboeli N, Ubaka U, Chukwuemeka M and Aguwa CN. (2014). Effects of an additional pharmaceutical care intervention versus usual care on clinical outcomes of Type 2 diabetes patients in Nigeria: A comparative study. Scientific Research and Essays 9: 548-556.
Al Hamarneh YN, Hemmelgarn BR, Hassan I, Jones CA and Tsuyuki RT. (2017). The effectiveness of pharmacist interventions on cardiovascular risk in adult patients with type 2 diabetes: The Multicentre Randomized Controlled RxEACH Trial. Canadian Journal of Diabetes 41: 580-586.
Mourão AOM, Ferreira WR, Martins MAP, Reis, AMM, Carrillo MRG, Guimarães AG and Ev LS. (2013). Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial. International Journal of Clinical Pharmacy 35: 79-86.
Sriram S, Chack LE, Ramasamy R, Ghasemi A, Ravi, TK and Sabzghabaee AM. (2011). Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. The Official Journal of Isfahan University of Medical Sciences 4: S412-418.
Chung WW, Chua SS, Lai PSM and Chan SP. (2014). Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Preference and Adherence 8: 1185-1194.
Chen JH Ou HT, Lin TC, Lai ECC and Kao YHY. (2016). Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial. International Journal of Clinical Pharmacy 38: 88-95.
Jameson JP and Baty PJ. (2010). Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. The American Journal of Managed Care 16: 250-255.
Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP and Giri M. (2011). Effectiveness of a community pharmacist
intervention in diabetes care: a randomized controlled trial: Effectiveness of a pharmacist intervention in diabetes care. Journal of Clinical
Pharmacy and Therapeutics 36: 602-613.
Correr CJ, Pontarolo R, Wiens A, Rossignoli P, Melchiors AC, Radominski R and Fernandez-Llimós F. (2009). Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies. Arquivos Brasileiros de Endocrinologia &
Metabologia 53: 825-833.
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A and Schünemann HJ. (2008). Rating quality of evidence and streng of
recommendations: Going from evidence to recommendations. British Medical Journal 336: 1049-1051.
Canfield SE and Dahm P. (2011). Rating the quality of evidence and the strength of recommendations using GRADE. World Journal of Urology 29: 311-317.
Higgins JP and Green S. (2011). Cochrane handbook for systematic reviews of interventions 5.1. 0. The Cochrane Collaboration, 33-49.
Chan CW, Siu SC, Wong CKW and Lee VWY. (2012). A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. Journal of Cardiovascular Pharmacology and Therapeutics 17: 57-64.
Clifford RM, Davis WA, Batty KT, Davis TME and Fremantle Diabetes Study (2005). Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 28: 771-776.
Guirguis L Johnson JA, Farris KB, Tsuyuki RT and Toth EL. (2001). A pilot study to evaluate the impact of pharmacists as certified diabetes educators on the clinical and humanistic outcomes of people with diabetes. Canadian Journal of Diabetes Care 25, 266-276.
Jaber LA, Halapy H, Fernet M, Tummalapalli S and Diwakaran H. (1996). Evaluation of a pharmaceutical care model on diabetes
management. Annals of Pharmacotherapy 30: 238-243.
Jarab AS, Alqudah SG, Mukattash TL, Shattat G and Al-Qirim T. (2012). Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. Journal of managed care pharmacy 18: 516-526.
Kandasamy K, Konakalla M, Sebastian J, Natarajan A, Rajagopal SS and Ramanathan S. (2017). A Pilot Study on the Impact of Pharmacist Intervention in Type-2 Diabetes Mellitus Counselling Program in a Rural Community. Indian Journal of Pharmaceutical Sciences 79: 701-706.
Ramanatha KV and Santhosh YL. (2011). Impact of clinical pharmacist provided patient education on QOL outcome in type II diabetes mellitus in rural population. Asian Journal of Pharmacy and Clinical Research 4: 15-20.
Schapansky LM, Johnson JA, Tsuyuki RT and Toth EL. (2000). A pilot study assessing the impact of community pharmacists' care on the clinical and humanistic outcomes of people with type 2 diabetes. 59. Institute of Health Economics Working Paper 00-13
Scott DM, Boyd ST, Stephan M, Augustine SC and Reardon TP. (2006). Outcomes of pharmacistmanaged diabetes care services in a community health center. American Journal of Health-System Pharmacy 63: 2116-2122.
Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R and Johnson JA. (2011). Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 34: 20-26.
Soorapan S. (2002). Assessing pharmacist's intervention in supporting the management of Type 2 diabetes in a primary care setting. RobertGordon University. Available fromttp:// www.rgu.ac.uk/staff-and-currentstudents/ library/librarypolicies/repository-policies).
Aguiar PM, da Silva CHP, Chiann C, Dórea EL, Lyra DP and Storpirtis S. (2018). Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. Journal of Evaluation in Clinical Practice 24: 22-30.
Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, Dittus RS, Weinberger M and Pignone MP. (2005). A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. The American Journal of Medicine 118: 276-284.
Odegard PS, Goo A, Hummel J, Williams KL and Gray SL (2005). Caring for poorly controlled diabetes mellitus: a randomized pharmacist
intervention. The Annals of Pharmacotherapy 39: 433-440.
Adepu SPR, Sam S, Omanakuttan C, Ramanatha KV and Yegurla Y. (2018). Assessment of pharmacist mediated education on health related quality of life in type 2 diabetes mellitus patients in rural south Indian population. Innovare Journal of Health Sciences 6: 55-58.
Sarkadi A and Rosenqvist U. (2004). Experiencebased group education in Type 2 diabetes: a randomised controlled trial. Patient Education and Counseling 53: 291-298.
Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL and Vijan S. (2005). Proactive case management of high-risk patients with type 2
diabetes mellitus by a clinical pharmacist: a randomized controlled trial. American Journal of Managed Care 11: 253-260.
Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR., and Cushing, G. (2012). Pharmacist assisted medication program enhancing the
regulation of diabetes (PAMPERED) study. Journal of the American Pharmacists Association 52: 613-621.
Korcegez EI, Sancar M and Demirkan K. (2017). Effect of a Pharmacist-Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. Journal of Managed Care & Specialty Pharmacy 23: 573-582.
Fornos JA, Andrés NF, Andrés JC, Guerra MM and Egea B. (2006). A Pharmacotherapy Follow-Up Program in Patients with Type-2 Diabetes in Community Pharmacies in Spain. Pharmacy World & Science 28: 65-72.
Jahangard-Rafsanjani Z, Sarayani A, Nosrati M, Saadat N, Rashidian A, Hadjibabaie M, Ashouri A,
Radfar M, Javadi M and Gholami K. (2015). Effect
of a community pharmacist-delivered diabetes
support program for patients receiving specialty
medical care: a randomized controlled trial.
Diabetes Education 41: 127-135.
Sarayani A, Mashayekhi M, Nosrati M, JahangardRafsanjani Z, Javadi M, Saadat N, Najafi S and Gholami K. (2018). Efficacy of a telephone-based intervention among patients with type-2 diabetes; a randomized controlled trial in pharmacy practice. International Journal of Clinical Pharmacy 40: 345-353.
Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, Lau P, Peterson G, Stewart K, Taylor S, et al. (2007). The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabetic Medicine 24: 677-683.
Farsaei S, Sabzghabaee AM, Zargarzadeh AH and Amini M. (2011). Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. Journal of Research in Medical Sciences 16: 43-49.
Berenguer B, La Casa C, de la Matta MJ, and Martin-Calero MJ. (2004). Pharmaceutical Care: Past, Present and Future. Current Pharmaceutical Design 10: 3931-3946.
Decastro M, Fuchs F, Costasantos M, Maximiliano P, Gus M, Beltramimoreira L and Cardosoferreira M. (2006). Pharmaceutical Care Program for Patients with Uncontrolled HypertensionReport of a Double-Blind Clinical Trial with Ambulatory Blood Pressure Monitoring. American Journal of Hypertension 19: 528-533.
Sadik A, Yousif M and McElnay JC. (2005). Pharmaceutical care of patients with heart failure. British Journal of Clinical Pharmacology 60: 183-193.
Belaiche S, Romanet T, Bell R, Calop J, Allenet B and Zaoui P. (2012). Pharmaceutical care in chronic kidney disease: experience at Grenoble University Hospital from 2006 to 2010. Journal of Nephrology 25: 558-565.
Wang HY, Chan ALF, Chen MT, Liao CH and Tian YF. (2008). Effects of Pharmaceutical Care Intervention by Clinical Pharmacists in Renal
Transplant Clinics. Transplantation Proceedings 40: 2319-2323.
Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, Van Tongelen I, Remon JP, Boussery K and Brusselle G. (2014).Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial: The PHARMACOP trial. British Journal of Clinical Pharmacology 77: 756-766.
Bluml BM, McKenney JM and Cziraky MJ. (2000). Pharmaceutical care services and results in project ImPACT: hyperlipidemia. Journal of the American Pharmacists Association 40: 157-165.
Mangiapane S, Schulz M, Mühlig S, Ihle P, Schubert I and Waldmann HC. (2005). Community Pharmacy-Based Pharmaceutical Care for Asthma Patients. Annals of Pharmacotherapy 39: 1817-1822.
Santschi V, Chiolero A, Burnand B, Colosimo AL and Paradis G. (2011). Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Archives of Internal Medicine 171: 1441-1453.